Emerging concepts in heart failure management and treatment: focus on vericiguat
暂无分享,去创建一个
[1] Dave L Dixon,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. , 2022, Journal of cardiac failure.
[2] D. Atar,et al. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction , 2022, European journal of heart failure.
[3] M. Emdin,et al. Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis , 2022, Journal of clinical medicine.
[4] G. Sinagra,et al. [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.
[5] H. Hillege,et al. A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. , 2021, JACC. Heart failure.
[6] P. Ponikowski,et al. Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). , 2021, Circulation.
[7] P. Ponikowski,et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial , 2021, European journal of heart failure.
[8] P. Ponikowski,et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial , 2021, European journal of heart failure.
[9] Sanjiv J. Shah,et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. , 2020, JAMA.
[10] M. Emdin,et al. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis , 2020, Cardiovascular Drugs and Therapy.
[11] P. Ponikowski,et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. , 2020, JACC. Heart failure.
[12] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[13] M. Radtke,et al. Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies , 2020, Clinical Pharmacokinetics.
[14] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[15] I. Buchan,et al. Do patients have worse outcomes in heart failure than in cancer? A primary care‐based cohort study with 10‐year follow‐up in Scotland , 2017, European journal of heart failure.
[16] W. Sessa,et al. Contemporary Approaches to Modulating the Nitric Oxide–cGMP Pathway in Cardiovascular Disease , 2017, Circulation research.
[17] Sanjiv J. Shah,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study , 2017, European heart journal.
[18] Sanjiv J. Shah,et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.
[19] M. Vaduganathan,et al. The vulnerable phase after hospitalization for heart failure , 2015, Nature Reviews Cardiology.
[20] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[21] W. Self,et al. The burden of acute heart failure on U.S. emergency departments. , 2014, JACC. Heart failure.
[22] I. Piña,et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.
[23] P. Ferdinandy,et al. Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signaling , 2007, British journal of pharmacology.
[24] L. Liaudet,et al. Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.
[25] O. V. Evgenov,et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.
[26] U. Walter,et al. Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase. , 2004, Acta biochimica Polonica.
[27] Charles D Searles,et al. The nitric oxide pathway and oxidative stress in heart failure. , 2002, Congestive heart failure.